Zydus Life Science

868.85
+24.45
(2.90%)
Market Cap
87,426.64 Cr
EPS
38.14
PE Ratio
18.74
Dividend Yield
0.36 %
Industry
Healthcare
52 Week High
1,324.30
52 Week Low
795.00
PB Ratio
3.89
Debt to Equity
0.05
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+44.44 %
+44.44 %
Hold
Hold+37.04 %
+37.04 %
Sell
Sell+18.52 %
+18.52 %

Company News

View All News
Caret
positive
Zydus Lifesciences Receives FDA Approval for Deflazacort Tablets2 days ago
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (FDA) for Jaythari (Deflazacort) tablets in various strengths: 6 mg, 18 mg, 30 mg, and 36 mg. This approval allows the company to market these tablets in the United States.
positive
Zydus Lifesciences: FDA Approves Jaythari for Duchenne Muscular Dystrophy3 days ago
Zydus Lifesciences received USFDA approval for Jaythari (Deflazacort) Tablets in 6 mg, 18 mg, 30 mg, and 36 mg strengths to treat Duchenne muscular dystrophy in patients 5 years and older. Manufacturing will occur at Doppel Farmaceutici S.r.l. in Italy. Zydus now has 424 USFDA approvals. The company also incorporated a subsidiary in France, Zydus MedTech (France) SAS.
positive
Zydus Lifesciences: Establishes French Subsidiary for Amplitude Surgical Acquisition3 days ago
Zydus Lifesciences has incorporated a wholly owned subsidiary, Zydus MedTech (France) SAS, on April 10, 2025, to acquire an 85.6% stake in Amplitude Surgical SA for €256.8 million. The company plans a subsequent tender offer for remaining shares and potential delisting.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
#8 87,426.64
#3 18.74
#6 19,831.50
#5 13.82
#4 3,831
#4 29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
20.05 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
2,269
2,291
2,286
2,300
2,310
2,232
2,360
2,266
2,479
2,127
3,165
3,206
3,197
2,870
2,875
3,547
3,658
3,429
3,271
3,555
3,672
3,462
3,663
3,645
3,551
3,971
6,106
3,590
3,821
3,989
3,993
4,199
4,890
5,089
4,313
4,403
5,526
6,110
5,182
5,181
Expenses
1,792
1,807
1,740
1,768
1,784
1,763
1,841
1,907
2,004
1,909
2,365
2,404
2,399
2,249
2,273
2,738
2,932
2,864
3,009
2,947
3,013
2,724
2,977
2,867
2,916
3,092
2,860
2,895
3,103
3,251
3,319
3,301
4,359
3,650
3,224
3,403
3,903
4,124
3,776
3,882
EBITDA
477
484
546
532
526
468
519
359
476
218
800
802
798
621
601
809
726
565
262
608
658
738
686
779
635
879
3,246
695
718
738
673
898
532
1,439
1,089
1,000
1,623
1,986
1,407
1,299
Operating Profit %
20 %
20 %
23 %
22 %
21 %
20 %
21 %
15 %
17 %
9 %
25 %
24 %
24 %
19 %
20 %
22 %
19 %
16 %
7 %
17 %
17 %
20 %
17 %
20 %
19 %
21 %
22 %
18 %
17 %
17 %
16 %
21 %
10 %
28 %
24 %
22 %
27 %
32 %
26 %
24 %
Depreciation
76
69
73
74
76
84
86
90
114
122
126
147
144
142
148
154
156
172
172
174
179
173
175
176
175
183
177
177
185
181
182
182
179
180
184
195
205
215
234
229
Interest
16
12
13
12
16
14
15
7
10
22
41
13
15
35
36
46
77
89
90
81
83
68
45
27
23
27
30
31
39
34
35
33
28
18
9
20
35
32
25
32
Profit Before Tax
426
519
545
537
498
441
435
324
412
154
712
722
724
570
535
672
606
394
122
457
522
588
524
617
526
777
3,135
598
558
673
648
781
484
1,328
1,006
947
1,550
1,900
1,271
1,184
Tax
69
51
60
97
-74
36
46
-6
20
9
200
168
125
102
107
150
124
69
28
86
108
102
89
89
-210
135
123
87
105
96
122
149
125
195
203
157
304
417
351
158
Net Profit
357
468
485
440
572
405
389
331
393
145
513
553
599
467
428
522
482
325
94
371
414
487
435
528
735
643
3,012
511
453
576
526
631
358
1,134
803
790
1,246
1,483
920
1,026
EPS in ₹
17.11
22.47
6.46
4.21
5.59
3.89
3.71
3.16
3.77
1.35
4.92
5.31
5.77
4.50
4.08
4.99
4.40
2.97
1.05
3.65
3.83
4.43
4.62
5.15
6.64
5.74
29.32
4.89
3.88
5.06
5.15
6.15
2.93
10.74
7.91
7.80
11.69
14.11
9.06
10.17

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,231
12,133
12,189
11,521
12,369
Current Assets
4,227
4,280
6,022
8,230
8,498
8,715
8,716
12,095
10,008
11,420
Capital Work in Progress
798
951
1,543
1,527
837
742
783
726
1,201
2,423
Investments
121
416
435
746
674
765
830
3,288
1,547
1,221
Other Assets
4,776
5,436
7,488
9,310
9,809
9,950
10,139
11,593
11,488
13,269
Total Liabilities
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
Current Liabilities
3,285
3,461
5,306
6,083
7,343
8,269
7,861
7,827
5,527
5,340
Non Current Liabilities
1,342
1,255
2,799
3,047
4,461
3,707
1,094
915
541
1,840
Total Equity
4,421
5,835
7,116
8,936
11,679
11,710
14,930
19,054
19,688
22,102
Reserve & Surplus
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
Share Capital
102
102
102
102
102
102
102
102
101
101

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
178
99
756
-3
-811
399
-91
219
-170
-75
Investing Activities
-465
-860
-2,872
-974
-3,977
-1,004
-837
-1,018
1,542
-1,492
Operating Activities
994
1,894
1,312
919
1,282
2,932
3,294
2,105
2,689
3,228
Financing Activities
-351
-935
2,316
52
1,885
-1,528
-2,548
-868
-4,400
-1,810

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
5.72 %
5.59 %
7.52 %
7.53 %
DIIs
11.11 %
10.43 %
11.22 %
11.78 %
12.78 %
11.92 %
12.94 %
13.69 %
13.60 %
13.23 %
13.09 %
12.79 %
12.63 %
12.64 %
10.65 %
10.65 %
Government
0.19 %
0.07 %
0.07 %
0.07 %
0.08 %
0.08 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.16 %
7.31 %
7.38 %
7.40 %
7.81 %
8.02 %
7.60 %
7.04 %
6.42 %
5.97 %
5.67 %
5.60 %
5.29 %
5.37 %
5.48 %
5.47 %
Others
7.66 %
7.32 %
6.44 %
5.87 %
4.46 %
5.11 %
4.48 %
4.29 %
5.00 %
5.82 %
6.26 %
6.63 %
1.38 %
1.43 %
1.37 %
1.36 %
No of Share Holders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 3.5 3.5 3.5 3.5 2.5 6 3 0.00
Dividend Yield (%) 0.00 0.85 1.01 1.31 0.79 1 0.51 0.6 0.34 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
Incorporation Of A Wholly Owned Subsidiary In France3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20185 days ago
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 28, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMar 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 08, 2025
Revised ESG ScoreMar 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Demand Notice Received By Zydus Healthcare Limited A Wholly Owned Subsidiary Company From GST DepartmentMar 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Intimation Of ESG RatingFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Integrated Filing (Financial)Feb 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024Feb 05, 2025
Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024Feb 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 26, 2025
Demand Notice By GST DepartmentJan 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 22, 2025
Demand Notice By GST DepartmentJan 21, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company For The Quarter / Nine Months Ended On December 31 2024Jan 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 18, 2025

Technical Indicators

RSI(14)
Neutral
44.56
ATR(14)
Less Volatile
32.72
STOCH(9,6)
Neutral
36.97
STOCH RSI(14)
Neutral
36.33
MACD(12,26)
Bearish
-3.22
ADX(14)
Weak Trend
19.08
UO(9)
Bearish
50.97
ROC(12)
Downtrend And Accelerating
-5.94
WillR(14)
Neutral
-52.25

About Zydus Life Science

Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(24 Years, 19 days)
Chairperson NamePankaj R Patel